Insulin Market Size & Share 2026-2035

Insulin Market Size

The global insulin market was valued at USD 29.2 billion in 2025. The market size is estimated to grow from USD 30.7 billion in 2026 to USD 41.4 billion in 2035, growing at a CAGR of 3.4% from 2026 - 2035, according to the latest report published by Global Market Insights Inc.

The increasing prevalence of diabetes, particularly type 2 diabetes globally, due to lack of physical activity, increased obesity, and an aging population, is a major growth factor for the market. Other factors such as an unhealthy lifestyle, increased calorie intake and glycemic load, genetic predisposition, and stress also play a critical role in the development of diabetes.
 

The International Diabetes Federation (IDF) identifies diabetes as one of the rapidly growing non-communicable chronic diseases of the 21st century. In 2021, it was estimated that 537 million people had diabetes, and this number is projected to reach 643 million by 2030 and 783 million by 2045. Insulin therapy is a critical component in managing diabetes. It helps keep blood sugar under control and prevents diabetes complications. Thus, such a high prevalence of diabetes cases increases the demand for effective therapeutics, thereby driving insulin market growth. Furthermore, there has been a rise in the adoption of early medical interventions as well as an increase in education surrounding diabetes, which fuels the demand for insulin.
 

Insulin is a hormone that lowers the level of glucose in blood. It is made by the beta cells of the pancreas and released into the blood when the glucose level rises, such as after eating. Insulin helps glucose enter the body's cells, where it can be used for energy or stored for future use. In diabetes, the pancreas does not make enough insulin, or the body cannot respond normally to the insulin that is made. This causes the glucose level in the blood to rise. This market includes various types of insulin formulations, such as rapid-acting, short-acting, intermediate-acting, long-acting, and premixed insulin, as well as biosimilar insulins.
 

The global insulin market is highly consolidated, with a few multinational pharmaceutical companies dominating supply and innovation. Notably, Novo Nordisk, Eli Lilly, and Sanofi collectively account for more than 90% of the market by value, highlighting strong market concentration. These players drive market growth through continuous insulin innovation, expansion of analog and biosimilar portfolios, strategic partnerships, advanced delivery device development, and strong global manufacturing and commercialization capabilities that enhance treatment access and adoption.

Insulin Market Trends

• The surge in diabetes cases worldwide is one of the leading factors driving the demand for insulin. For instance, as per a report published by The Lancet, more than half a billion people are living with diabetes worldwide, including men, women, and children of all ages in every country. This number is projected to more than double to 1.3 billion people in the next 30 years, with every country seeing an increase.
   
• This escalation in the number of patients suffering from diabetes has increased the need for insulin as a critical treatment option to manage blood sugar levels, especially for patients with type 1 diabetes and advanced-stage type 2 diabetes.
   
• Obesity significantly increases the risk of diabetes. In 2024, the NCD Risk Factor Collaboration (NCD-RisC) published findings that estimate that more than one billion people in the world are now living with obesity, nearly 880 million adults and 159 million children and adolescents aged 5–19 years. Further, childhood obesity has increased rapidly in recent years. According to UNICEF’s estimates, in the year 2000 around 30 million children under the age of 5 years were living with overweight or obesity, rising to 37 million children in 2022.
   
• Obesity is a common risk factor that can lead to the development of prediabetes and type 2 diabetes. Thus, such an alarming rise in obesity increases the predisposition to diabetes, consequently driving the insulin market growth.
   
• The growing awareness about diabetes management and the increasing availability of insulin therapies in emerging markets further fuels this demand.
   
• Moreover, government support and policies have also greatly aided in the progression of the market. For instance, the ‘Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) initiative by the government of India provides quality generic medicines, including insulin, at affordable prices to all in collaboration with the state governments.
   
• Such initiatives provide greater access to insulin therapies, thereby supporting market growth.
   

Insulin Market Analysis

Based on the type, the insulin market is segmented into human insulin and insulin analog. The insulin analog segment accounted for the highest market share and was valued at USD 22.3 billion in 2025.
 

• Insulin analogs dominate the market due to their unmatched effectiveness, safety, and greater compliance when compared to traditional human insulin. Insulin analogs are associated with lower risks of hypoglycemia, lower levels of postprandial glucose excursions, better patient adherence, greater quality of life, and higher satisfaction with treatment.
   
• Insulin analogs provide dosing flexibility, which may improve patient satisfaction and adherence to therapy, and are easy to administer. Also, long-acting insulin analogs, particularly insulin detemir, are associated with less weight gain.
   
• In addition, compared with regular human insulin, insulin analogs offer the advantages of faster subcutaneous absorption, an earlier and greater insulin peak, and a shorter duration of action.
   
• Further, the introduction of biosimilar insulin analogs has greatly broadened the demographic and geographic acceptance, thus enhancing the utilization of these therapies.
   
• Moreover, the consistent development and innovation of next-generation insulin analogs will likely continue to increase their share of the market.
   

Based on the product, the insulin market is categorized into long-acting insulin, rapid-acting insulin, combination insulin, biosimilar, and other products. The long-acting insulin segment dominated the market with a 45.3% market share in 2025.
 

• Long-acting insulin is designed for slow release, ensuring a consistent baseline insulin level in the blood over an extended period. It acts slowly due to the precipitation caused when insulin is injected subcutaneously.
   
• Further, the long-acting insulin, which can last up to 42 hours, decreases patients’ insulin injection frequency and helps them adhere to the treatment.
   
• These medications are effective at mimicking the secretion of natural basal insulin, which aids in controlling stable blood glucose levels, reducing the chances of hypoglycemia. Hence, all these factors increase patient compliance with long-acting insulin, thereby increasing the adoption of long-acting insulin products.
   
• Further, the development and commercialization of a vast range of long-acting insulins by insulin manufacturers has significantly contributed to their high market share.
   
• Also, favorable reimbursement, technological advancement in the delivery devices of insulin, and the increased focus on personalized care for diabetes management are other factors which shall continue to ensure the dominance of the long-acting insulin segment in the insulin market.
   
• On the other hand, the rapid-acting insulin segment held the second-highest market share of 31.3% in 2025, owing to quick blood glucose control after meals, widespread use in daily insulin regimens, and increasing adoption alongside insulin pumps and basal insulin therapies.

Based on the application, the insulin market is categorized into type 1 diabetes mellitus, type 2 diabetes mellitus, and gestational diabetes. The type 1 diabetes mellitus segment dominated the market in 2025 with a market share of 75.2% and is anticipated to witness growth at a CAGR of 3.3% over the forecast years.
 

• As of 2021, an approximate total of 8.4 million individuals were diagnosed with type 1 diabetes mellitus (T1DM) all across the globe, with 500,000 new cases reported that year alone. The number of T1DM sufferers is projected to increase to 13.5–17.4 million by 2040. The rising population of patients with type 1 diabetes is expected to drive the growth of the insulin market.
   
• Type 1 diabetes occurs in patients with insulin deficiency. Patients with type 1 diabetes need to inject insulin every day, often up to 4 or 5 times per day.
   
• Thus, type 1 diabetes patients have a significant and lifelong reliance on external insulin for managing the disease. Unlike type 2 diabetes, where oral medication and lifestyle changes could be effective, type 1 diabetes mellitus patients need frequent insulin delivery to control blood sugar levels and avoid complications.
   
• Moreover, the development of new technologies in rapid-acting and long-acting insulin formulations also improves patient outcomes, making a positive contribution to the dominant share of type 1 diabetes mellitus in the insulin market.
   
• The type 2 diabetes segment, on the other hand, is anticipated to grow at a CAGR of 3.9% over the analysis period, driven by the rising global prevalence of type 2 diabetes, increasing disease diagnosis rates, and gradual intensification of treatment regimens requiring insulin therapy in advanced disease stages.
   

Based on the distribution channel, the global insulin market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment dominated the market in 2025 and is expected to reach USD 21.5 billion by 2035.
 

• Hospital pharmacies hold a significant market share of the market due to high diabetes-related hospital admissions and the essential role of hospitals in the treatment of advanced diabetes.
   
• Also, hospitals maintain stocks of various insulin products, including fast-, slow-, and mixed-acting insulin for different patients.
   
• Furthermore, the growing incidence of complications such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) requires hospital-based insulin treatment, which further increases the need for hospital pharmacies.
   
• Thus, given the rising population of diabetes patients and the growing use of insulin in hospitals, it is anticipated that the hospital pharmacies segment will sustain its dominant share of the insulin market.
   
• The online pharmacies segment is anticipated to witness strong growth over the forecast years due to increasing digital healthcare adoption, convenience of home delivery, competitive pricing, and expanding availability of insulin through regulated e-pharmacy platforms.

North America Insulin Market

The North America insulin industry dominated the revenue share of 40.1% in 2025.
 

• North America holds a leading share in the market, strongly supported by the substantial diabetes burden and high insulin utilization across the region. According to the U.S. Centers for Disease Control and Prevention (CDC), over 2 million Americans are living with type 1 diabetes, including about 314,000 children and adolescents.
   
• In addition, national estimates suggest that around 8 million Americans depend on insulin therapy to manage their condition, highlighting significant product utilization within the region.
   
• The combination of this large patient base, strong diagnosis rates, advanced healthcare infrastructure, and widespread availability of insulin analogs and delivery technologies collectively reinforces North America’s dominant revenue contribution to the market.
   

The U.S. insulin market size reached USD 10.6 billion in 2025.
 

• Several attributes, such as high diabetes rates in the country, a robust healthcare system, and considerable allocation of funds towards insulin R&D help the U.S. retain a major market portion of the global insulin industry.
   
• For example, 1.2 million Americans are diagnosed with diabetes every year. In 2021, 38.4 million Americans, or 11.6% of the population, had diabetes, of which 2 million Americans had type 1 diabetes, including about 304,000 children and adolescents. Further, around 97.6 million Americans aged 18 and older had prediabetes.
   
• Such a high volume of patients in the country increases the demand for insulin, thereby driving the market growth.
   
• In addition, the presence of leading insulin manufacturers, such as Eli Lilly, Novo Nordisk, and Sanofi, in the country, who constantly supply innovative and effective insulin products, further boosts the market growth.
   

Europe Insulin Market

The Europe insulin industry is anticipated to witness significant growth at a CAGR of 3.7% over the forecast years.
 

• High regional market growth is owing to its well-developed healthcare framework alongside strong governmental diabetes support and a high diabetes population.
   
• As per the Diabetes Atlas, 2000 - 2045, Europe has the highest number of children and adolescents with type 1 diabetes (295,000) as well as the highest incidence annually with 31,000 new cases per year.
   
• Further, nations such as Germany, France, and the UK have a substantial diabetic population which greatly increases the demand for insulin.
   
• Also, the region’s growth is further bolstered by the favorable reimbursement policies alongside government programs aimed at improving diabetes management.
   

Germany insulin market is anticipated to witness considerable growth over the analysis period.
 

• The growth of Germany’s insulin industry is being driven by the rising incidence of diabetes in the country along with its well-developed healthcare system.
   
• In Germany, about 8.5 million people suffer from diabetes. According to estimates, about 2 million people live with undiagnosed diabetes. The prevalence of diabetes in German population is estimated to be 10%.
   
• In addition, higher utilization of insulin is made possible by the German government’s supportive reimbursement policies and investment in diabetes management programs.
   
• Moreover, the presence of key players such as Sanofi, Novo Nordisk, and Eli Lilly fosters growth by innovation and provision of various new products, thereby strengthening the market.
   

Asia Pacific Insulin Market

The Asia Pacific region demonstrates significant growth potential in the global insulin industry.
 

• The Asia Pacific insulin industry is poised for high growth owing to the rapid proliferation of diabetes, growing health expenditures, and enhanced healthcare access.
   
• Countries such as China and India together make up a sizable portion of the diabetic population, which increases the demand for insulin products. More than 60% of the people with diabetes live in Asia, with almost half of the diabetic population in China and India combined.
   
• Additionally, government policies aimed at controlling diabetes, like federal health programs and subsidized insulin therapy, are also helpful in accelerating the market growth.
   

India insulin market is anticipated to witness high growth in Asia Pacific market.
 

• According to the Indian Council of Medical Research (ICMR) in 2022, around 95,600 children below the age of 14 years in India suffer from type 1 diabetes. This number is set to increase due to various factors such as urban migration, sedentary living, and change in eating habits, thereby driving the growth opportunity for insulin industry.
   
• In addition, supportive government initiatives and price subsidies increase the treatment adoption rates, thereby propelling the overall market growth.
   

Latin America Insulin Market

Brazil insulin industry is experiencing significant growth in the Latin America market.
 

• With the surge in diabetes cases and diabetes care awareness, Brazil stands out in Latin America market. The country is one of the most economically developed countries in Latin America and has more than 16 million diabetic adults. It is estimated that 7.7 million people (20–79 years) in the country have not yet been diagnosed, representing an under-diagnosis rate of 46.0%. This rising rate of diabetes has created strong growth opportunities for the insulin market in the country.
   
• Additionally, the government’s focus on improving diabetes treatment, which includes subsidized insulin programs through the Unified Health System (SUS), is facilitating the rise in demand.
   

Middle East and Africa Insulin Market

Saudi Arabia insulin industry is poised to witness rapid growth in the Middle East and Africa market.
 

• In Saudi Arabia, the insulin industry is growing due to increasing cases of diabetes in the country.  For instance, in 2021, approximately 18.2% of Saudi Arabia adult population was estimated to have diabetes, this number is projected to increase to 24.3% by 2026. The rising adoption of sedentary lifestyles coupled with high obesity is a major contributor to high diabetes rates and consequent high demand for insulin therapies.
   
• Also, the increase in elderly population and greater understanding of diabetes control is likely to drive the growth of insulin consumption over the next few years.
   

Insulin Market Share

The major players operating in the insulin industry include Eli Lilly, Novo Nordisk, and Sanofi. These top 3 players account for approximately over 90% of the insulin industry. These market players focus on strategies such as mergers, acquisitions, innovative product development and launches, expansion, and collaboration to generate more revenue and withstand market competition. For instance, in December 2024, Eli Lilly announced a USD 3 billion expansion of its Wisconsin manufacturing facility. This investment will extend the company's global parenteral (injectable) product manufacturing network, helping to meet the growing demand for its diabetes, obesity and future pipeline medicines across therapeutic areas.
 

Moreover, businesses are allocating more resources to research and next-generation formulation development work, including ultra rapid acting and biosimilar insulin drugs which aim to be more effective, cheaper, and easier to access. To serve price sensitive regions, these producers are also introducing cheaper products and adopting cost containment measures so that insulin therapy would be affordable to patients around the globe.
 

Insulin Market Companies

Some of the prominent players operating in the insulin industry include:

• Adocia
• Biocon
• Boehringer Ingelheim International
• Eli Lilly and Company
• Gan & Lee Pharmaceuticals
• Gland Pharma
• Julphar
• MannKind Corporation
• Novo Nordisk
• Pfizer
• Sanofi
• Shanghai Fosun Pharmaceutical
• Tonghua Dongbao Pharmaceutical
• United Laboratories International
• Wockhardt
   
• Novo Nordisk

Novo Nordisk is one of the world’s leading insulin manufacturers with a strong global production and innovation footprint. In November 2023, Novo Nordisk announced an investment exceeding USD 6 billion to expand its manufacturing facilities in Denmark, aimed at increasing capacity for insulin and other diabetes therapies to meet rapidly growing global demand. This large-scale expansion strengthens Novo Nordisk’s supply capabilities amid the rising diabetes burden worldwide.
 

• Sanofi

Sanofi is among the leading world’s insulin producers. In December 2024, Sanofi has announced a significant investment of approximately about USD 1 billion to establish a new insulin production facility in Beijing, China. This marks Sanofi's largest single investment in the country to date, which is strategically along with bolstering its manufacturing infrastructure due to the surging diabetes epidemic in China. The China market for treatment of diabetes is huge; around 140 million people in the mainland, nearly 12% of its population, has diabetes. This will provide significant growth opportunities for Sanofi.
 

Insulin Industry News

• In December 2024, Adocia and Tonghua Dongbao announced the completion of the final dosing in a phase 3 clinical study of BioChaperone Lispro, an ultra-rapid insulin formulation aimed at treating type 2 diabetes. BioChaperone Lispro is designed to act faster than traditional insulins, potentially improving patient outcomes by allowing for more precise dosing during meals.
   
• In March 2023, Eli Lilly and Company announced price reductions of 70% for its most prescribed insulins and an expansion of its Insulin Value Program that caps patient out-of-pocket costs at USD 35 or less per month. These measures aim to improve insulin accessibility for people with diabetes amid rising costs in the healthcare system.
   
• In November 2022, Biocon Biologics Ltd., a subsidiary of Biocon Ltd. completed acquisition of the global biosimilars business of its partner Viatris Inc. This acquisition strengthened Biocon’s biosimilar product portfolio and improved its revenue generation.
   
• In May 2022, MannKind Corporation announced an agreement to acquire the V-Go insulin delivery device from Zealand Pharma A/S. This acquisition helped the company to enhance its offerings in diabetes management solutions.
   

The insulin market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 - 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Human insulin
• Insulin analog         

Market, By Product

• Rapid-acting insulin
• Long-acting insulin
• Combination insulin
• Biosimilar
• Other products

Market, By Application

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus
• Gestational diabetes

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE